Recent Patents on Biotechnology - Online First
Description text for Online First listing goes here...
21 - 24 of 24 results
-
-
Synthesis and Biological Properties of Formulated Skin Serum Containing Coelomic Fluid of Earthworm Eisenia fetida/andrei
Authors: Parisa Imeni, Mehdi Zarabi, Pegah Shakib and Ashkan DirbaziyanAvailable online: 07 May 2025More LessObjectivesIn this study, the coelomic fluid of Eisenia fetida/andrei species was used for the first time to prepare an anti-aging serum, and its antioxidant and antibacterial properties were investigated. In addition, its cytotoxicity on mouse fibroblast cells was measured as material for the production of natural anti-aging products.
Materials and MethodsThis study investigates the antibacterial, antioxidant, and cytotoxic properties of coelomic fluid extracted from Eisenia fetida/andrei. Earthworms were cultured for a year, and their coelomic fluid was extracted using an electroshock method, sterilized, and lyophilized into powder. Antibacterial activity was tested against Escherichia coli and Staphylococcus aureus using MIC assays. Antioxidant properties were evaluated using the DPPH radical scavenging assay. Cytotoxicity effects on L929 and NHEK cell lines were assessed using MTT assays. Oxidative stress and enzymatic activities were analyzed by measuring malondialdehyde (MDA) levels and catalase activity in NHEK cells treated with coelomic fluid. A serum formulation incorporating coelomic fluid was prepared and subjected to stability tests, including pH, temperature, mechanical, and heavy metal residue analysis. Antibacterial and antioxidant properties of the serum were also evaluated. Statistical analyses were conducted using SPSS software (version 0.26). Results highlight the multifunctional potential of coelomic fluid for biomedical and cosmetic applications.
ResultsCoelomic fluid exhibited antibacterial activity with MICs of 0.15 mg/mL for both E. coli and S. aureus, showing significant inhibition at higher concentrations. Ciprofloxacin and penicillin demonstrated stronger effects compared to the coelomic fluid. Antioxidant activity increased with concentration, achieving 77% inhibition at 10 mg/mL, with an IC50 of 10.67 mg/mL. Cytotoxicity analysis revealed no significant toxicity below 20 mg/mL, with enhanced cell viability at 2.5–5 mg/mL and restorative effects on fibroblasts at 10 mg/mL. Oxidative stress assays indicated reduced lipid peroxidation and increased catalase activity without inducing significant oxidative stress. Measurement of residues of mercury and lead in the sera showed that they were less than 0.01 ppm for mercury and less than 0.03 and 0.05 ppm for lead, respectively. These levels are below the U.S. Food and Drug Administration's approved limits for these metals. Aqueous serum containing coelomic fluid showed similar antibacterial and antioxidant properties, emphasizing its potential for cosmetic and pharmaceutical applications.
ConclusionsThese results show that the use of earthworm coelomic fluid in skin care serum slows the aging process and restores damaged cells. The results of the present study can be considered as a patent.
-
-
-
Molecular Variation of Methicillin-resistant Staphylococcus haemolyticus Isolated from Patients in Ramadi City, Iraq
Available online: 30 April 2025More LessBackgroundThe increasing prevalence of Staphylococcus haemolyticus infections in community and hospital settings presents a significant health challenge due to growing antibiotic resistance and biofilm formation.
ObjectiveThis study aims to:(1) perform a molecular analysis of prevalent native strains in Anbar, Iraq, (2) differentiate between various pathogenic strains using multilocus sequence typing (MLST) to enhance epidemiological and surveillance efforts by relevant patents on molecular diagnostics and pathogen typing. The objective is to trace the origins of these strains and distinguish between invasive and indigenous strains. While S. haemolyticus is generally part of the normal human microbiota, it can lead to serious infections in individuals with prior injuries or surgical procedures. It is particularly skilled at developing antibiotic resistance, making it a leading cause of hospital-acquired infections, largely through the staphylococcal cassette chromosome mec (SCCmec). Methicillin-resistant S. haemolyticus (MRSH) has developed resistance to oxacillin/cefoxitin through SCCmec acquisition, and hospital-associated MRSH strains are increasingly resistant to multiple antibiotics.
MethodologyThe preparation of blood agar medium followed the manufacturer's guidelines. After autoclaving at 121ºC for 15 minutes, the medium was cooled to 50ºC. The mixture was then thoroughly mixed and poured into sterile Petri dishes. This medium is used for isolating and cultivating bacteria, as well as for detecting hemolytic activity and identifying the type of hemolysis. Genomic extraction and molecular screening of multidrug-resistant (MDR) isolates were performed, followed by MLST analysis. Data were processed using the University of Nebraska Medical Center's pubMLST website.
ResultsTo explore the genetic relationships among S. haemolyticus strains, their genomic DNA was analyzed using MLST typing based on the protocol from the MLST Institute database. All S. haemolyticus isolates in the study underwent MLST gene screening through PCR to verify the presence of housekeeping genes (arc, SH1200, hemH, leuB, SH1341, cfxE, and ribose ABC). PCR electrophoresis results demonstrated successful amplification of all target genes, confirming their appropriateness for MLST analysis. Three isolates were recognized as novel global strains, designated ST153, ST154, and ST155. In addition, five other strains were previously registered as ST3, ST9, ST29, ST123, and ST124.
ConclusionThe findings diverge from the established global understanding of type distribution in Asia. To combat the spread of highly resistant strains, it is crucial to monitor virulence factors and antibiotic resistance closely.
-
-
-
Exploring the Two-Way Role: Biological and Anti-Epileptic Properties of Imidazole and 2-Mercaptobenzimidazole Derivatives
Authors: Geetika Goel and Jannat ul FirdousAvailable online: 25 April 2025More LessImidazole and 2-mercapto benzimidazole analogues are a group of molecules that have various biological activities and good therapeutic potential in the treatment of epilepsy. This review explores their dual role, focusing on their biological properties and anti-epileptic effects. A spectrum of biological activities is displayed by imidazole derivatives and 2- mercaptobenzimidazole, such as antifungal, antioxidant, anti-inflammatory, and antimicrobial actions, leading to their therapeutic flexibility apart from epilepsy treatment. Imidazole derivatives mechanistically modulate Gamma-Aminobutyric Acid (GABA) receptors, inhibit ion channels, and exert neuroprotective effects, enabling them to be used for seizure control. Their mechanisms of action involve modulation of oxidative stress pathways as well as providing neuroprotective effects against epilepsy. In terms of structure, both imidazole and 2-mercaptobenzimidazole derivatives have gone through extensive structure-activity relationship studies to enhance their biological and pharmacological aspects. However, numerous concerns, such as bioavailability, selectivity, and side effects, hinder their effective application in the treatment of various diseases. Looking forward, further research into novel derivatives and patented formulation strategies holds promise for enhancing efficacy and reducing adverse effects. This review consolidates current knowledge, emphasizing the multifaceted roles of imidazole and 2-mercapto benzimidazole derivatives in biological systems and their potential as anti-epileptic agents, thus providing insights for future research and clinical applications.
-
-
-
Intellectual Property Rights Effects on India's Pharmaceutical Industry
Authors: Virendra S. Gomase, Suchita P. Dhamane and Swati C. JagdaleAvailable online: 21 April 2025More LessThe Indian pharmaceutical industry took full advantage of the “process patent regime”. It aggressively pursued the expansion of its market share by offering the most reasonably priced generic versions of pharmaceuticals to emerging and developing nations. The Indian government remained neutral over the implementation of the TRIPS agreement until 2005. Indian pharmaceutical patent law is distinct from legislation in other nations in several ways, some of which are among the most critical intellectual property issues in the nation. Over the past thirty years, the lack of product patent protection has been a significant setback for the Indian pharmaceutical business. “Molecules” that were patented and protected internationally but which India failed to protect. The Act's ambiguity makes it common for opponents of pharmaceutical patents to file unreasonable serial pre-grant oppositions. In addition, the number of pre-grant opposition filings is surging exponentially. The potential for revocation, oppositions before and after the grant, and counterclaims in cases of infringement are just a few of the challenges that may arise during the process of a patent. The TRIPS Agreement compliance of the Indian patent system will be guaranteed by the Patents (Amendment) Rules, 2005, and the Patents (Amendment) Ordinance, 2004. Nonetheless, another notable accomplishment of the Ordinance and the Rules is the progressive change of the Indian patent prosecution system. In keeping with its international obligations, the Indian government is working to create a patent system that encourages technical development. Additionally, India is working to alleviate concerns about the inadequate enforcement of its current intellectual property rules.
-
Most Read This Month Most Read RSS feed
Most Cited Most Cited RSS feed
-
-
Gluconic Acid Production
Authors: Savas Anastassiadis and Igor G. Morgunov
-
- More Less